Prime Medicine (PRME) Other financing activities (2021 - 2022)
Prime Medicine posted quarterly Other financing activities of $1.4 million for Q4 2022, up 28.91% year-on-year from $1.1 million in Q4 2021, and up 87.67% on a QoQ basis from $746000.0 in Q3 2022.
Prime Medicine (PRME) has 2 years of Other financing activities data on file, last reported at $1.4 million in Q4 2022.
- For the quarter ending Q4 2022, Other financing activities rose 28.91% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2023 stood at $1.4 million (down 62.45% YoY), and the FY2022 full-year result was $4.0 million, up 272.19% from the prior year.
- Other financing activities for Q4 2022 stood at $1.4 million, up from $746000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $1.4 million in Q4 2022 and bottomed at $624000.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.40 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 746,000.00 |
| Sep 30, 2022 | 746,000.00 |
| Jun 30, 2022 | 624,000.00 |
| Jun 30, 2022 | 624,000.00 |
| Mar 31, 2022 | 1.27 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Dec 31, 2021 | 1.09 Mn |